X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to develop PDC*neo+, a personalized therapeutic vaccine for colorectal cancer using PDC*line Pharma's innovative PDC*line technology.
Lead Product(s): Dendritic Cell-based Vaccine
Therapeutic Area: Oncology Product Name: PDC*Neo
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: BioWin
Deal Size: $8.9 million Upfront Cash: Undisclosed
Deal Type: Financing January 17, 2024
Details:
PDC*lung01 is a vaccine administered via subcutaneous injection in combination with pemetrexed, being developed for non-small cell lung cancer.
Lead Product(s): PDC*lung01
Therapeutic Area: Oncology Product Name: PDC*lung01
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Details:
Results showed that in a large proportion of subjects PDC*lung01, in monotherapy and combined with pembrolizumab, induces a significant expansion of effector memory CD8+ T-cells specific to the tumor peptides carried by PDC*lung01.
Lead Product(s): PDC*lung01,Pembrolizumab
Therapeutic Area: Oncology Product Name: PDC*lung01
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
Proceeds will primarily be used to fund company’s phase I/II trial with PDC*lung01, a vaccine candidate for lung cancer associated with or not with anti-PD-1 treatment in NSCLC.
Lead Product(s): PDC*lung01,Pemetrexed
Therapeutic Area: Oncology Product Name: PDC*lung01
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Korea Investment Partners
Deal Size: $20.3 million Upfront Cash: Undisclosed
Deal Type: Series B Financing December 06, 2021
Details:
Funding will support company’s phase I/II trial with PDC*lung01 candidate in lung cancer.
Lead Product(s): PDC lung01
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Korean Investment Partners
Deal Size: $22.2 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
